{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"22","value":"10"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"28","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"The 6-month clinical benefit rate is defined as the percentage of participants with a response or stable disease (CR, PR, or SD) at 6 months. (CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by \\>= 50% of previously involved sites from nadir, SD: Not CR/PR or PD).","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Initial Single"},{"description":"Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Initial Dual"}],"paramType":"NUMBER","populationDescription":"Randomized Initial Cohort participants who received treatment (i.e. exclude cancel patients) Only.","reportingStatus":"POSTED","timeFrame":"At 6 months","title":"6-Month Clinical Benefit Rate [Initial Cohort]","type":"SECONDARY","unitOfMeasure":"percentage of participants"}